Skip to content

Longitudinal Description of Hemorrhoidal Pathology

Longitudinal Description of Hemorrhoidal Pathology

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04945408
Acronym
DeLPH
Enrollment
500
Registered
2021-06-30
Start date
2020-06-15
Completion date
2023-03-06
Last updated
2023-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhoids

Brief summary

Hemorrhoidal disease is a common cause of gastroenterology visits. In the United States, it is considered the 3rd most common gastrointestinal diagnosis with nearly 4 million scheduled or emergency visits. In France, self-reported questionnaires estimate that one person in five has suffered at least one hemorrhoidal attack in the past year.

Detailed description

Hemorrhoidal disease significantly alters the quality of life, can be life threatening in case of heavy bleeding and has a significant economic impact. However, there are still many unknowns regarding the different types of hemorrhoidal disease, its symptoms, its natural history, its etiology, its triggering and promoting factors, the associated pathologies, the therapeutic indications, etc. In addition, the therapeutic management is not consensual, especially since the therapeutic arsenal is constantly expanding over the last 20 years with the advent of minimally invasive surgical techniques. The aim of the work is to answer some of these questions on the basis of a prospective cohort of patients.

Interventions

None listed

Sponsors

Fondation Hôpital Saint-Joseph
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient whose age is ≥ 18 years * Consecutive patients consulting for hemorrhoidal disease at the proctology department of the Groupe Hospitalier Paris Saint-Joseph (GHPSJ) between January 1, 2020 and April 30, 2020 * French-speaking patient

Exclusion criteria

* Patient objecting to participation in the study * Patient under guardianship or curatorship * Patient deprived of liberty * Patient under court protection

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the effectiveness of the different treatments proposed according to the type of hemorrhoidal disease (internal, external or both)6 monthsAverage prolapse score before and after treatment according to the type of hemorrhoidal disease (internal, external or both).

Secondary

MeasureTime frameDescription
Evaluate the proportion of patients consulting for hemorrhoidal disease in the general proctology consultation of a specialized center that also receives emergencies6 monthsProportion of patients in the proctology department consulting for hemorrhoidal disease
Describe the various symptoms of hemorrhoidal disease6 monthsProportions of various symptoms of hemorrhoidal disease
Search for proctological pathologies associated with hemorrhoidal disease6 monthsPrevalence of proctological pathologies associated with hemorrhoidal disease
Determine potential risk factors for hemorrhoidal disease6 monthsCorrelations between potential risk factors and the development of hemorrhoidal disease

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026